Yuanmin Chang

Yuanmin Chang

Auto-generated profile, based on publicly available information

Yuanmin Chang

Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China; and

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YCYuanmin Chang
Yuanmin Chang
MBMengru Bai
Mengru Bai
QYQinghai You
Qinghai You
Background. To investigate the association between interleukins (IL‐1β, IL‐2, IL‐4, IL‐6, IL‐8, and IL‐10) and the disease severity of coronavirus disease 2019 (COVID‐19). Materials and Methods. We systematically searched records investigating the role of interleukins (IL‐1β, IL‐2, IL‐4, IL‐6, IL‐8, and IL‐10) in COVID‐19 patients in Web of Science, Pubmed, and Embase through December 2020. Data were extracted and pooled, and the weighted mean difference (WMD) and its 95% confidence interval (CI) were calculated. The funnel plot and the nonparametric trim and fill method were used to visualize and adjust the publication bias. Results. In total, 61 studies enrolled 14,136 subjects (14,041 patients and 95 healthy subjects) were enrolled in this meta‐analysis. Our results showed that serum IL‐2, IL‐4, IL‐6, and IL‐10 levels were elevated in COVID‐19 patients compared to healthy controls, and IL‐6, IL‐8, and IL‐10 levels were increased in severe COVID‐19 cases compared to nonsevere patients. Additionally, the levels of IL‐1β, IL‐6, and IL‐8 were elevated in nonsurvivor patients compared to survivors. For patients in the intensive care unit (ICU), IL‐6 and IL‐8 levels were increased than that in non‐ICU patients. Conclusions. Elevated levels of IL‐6, IL‐8, and IL‐10 were associated with the disease severity of COVID‐19, and elevated levels of IL‐1β, IL‐6, and IL‐8 were related to the prognosis of COVID‐19 patients, which could be used to evaluate COVID‐19 patients’ disease severity and prognosis.

2 November 2026 in Neurology
Verified
Journal Article
Closed access
SCShugang Cao
Shugang Cao
JDJing Du
Jing Du
TWTieyu Wu
Tieyu Wu
YCYuanmin Chang
Yuanmin Chang
HRHaitao Ren
Haitao Ren
XQXiaokun Qi
Xiaokun Qi